NK-1 RECEPTOR ANTAGONISTS AND ELETRIPTAN FOR THE TREATMENT OF MIGRAINE

摘要

The present invention relates to a method of treating or preventing migraine in a mammal, including a human, by administering to the mammal eletriptan or a pharmaceutically acceptable salt of eletriptan and an NK-1 receptor antagonist (e.g., a substance P receptor antagonist). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, eletriptan or a pharmaceutically acceptable salt of eletriptan and an NK-1 receptor antagonist.